2 results
Not approvedWill not start
Primary ObjectiveTo determine whether GWP42003-P affects the pharmacokinetic (PK) profile of stiripentol (STP) or valproate (VPA).Secondary Objective(s)To assess the safety and tolerability of GWP42003-P in the presence of STP or VPA.
Approved WMORecruiting
Objective: 1. Investigate the prevalence of ATTR in patients undergoing TAVR in the Netherlands.2. To determine whether ATTR influences the effectiveness of TAVR treatment on LV dysfunction.